title: A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
abstract: Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.
authors.affiliation: Brooke Army Medical Center, San Antonio, TX.
authors.forename: T R
authors.initials: TR
authors.lastname: Jenkins
authors.forename: C
authors.initials: C
authors.lastname: Tangen
authors.forename: J S
authors.initials: JS
authors.lastname: Macdonald
authors.forename: G
authors.initials: G
authors.lastname: Weiss
authors.forename: R
authors.initials: R
authors.lastname: Chapman
authors.forename: A
authors.initials: A
authors.lastname: Hantel
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046659:piroxantrone